AbbVie (BSP:ABBV34) Research & Development : R$38,301 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AbbVie Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. AbbVie's Research & Development for the three months ended in Dec. 2023 was R$9,442 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was R$38,301 Mil.

AbbVie Research & Development Historical Data

The historical data trend for AbbVie's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Research & Development Chart

AbbVie Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

26,297.53

32,818.04

39,143.22

34,147.55

37,605.97

AbbVie Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Research & Development	Get a 7-Day Free Trial															9,389.27	11,938.11	8,411.46	8,509.38	9,441.92

AbbVie Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$38,301 Mil.

AbbVie (BSP:ABBV34) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

AbbVie Research & Development Related Terms

Thank you for viewing the detailed overview of AbbVie's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

AbbVie (BSP:ABBV34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (BSP:ABBV34) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

ABBV:USA ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB:Germany ABBV:Canada ABBV:Austria

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

http://www.abbvieinvestor.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

AbbVie (BSP:ABBV34) Headlines

No Headlines